SCHEMBL9924154

SCHEMBL9924154

CCOC(=O)N[C@H]1CC[C@H](N/C(=N\C(=O)c2ccc(F)c(F)c2)NC(C)(C)C(F)(F)F)CC1

nearest known ligand 0.40

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 2/20 0.40
MCHR1 Q99705 6/20 0.37
DRD2 P14416 1/20 0.37
CYP2C9 P11712 3/20 0.36
MAPK14 Q16539 3/20 0.36
EPHX2 P34913 2/20 0.36
TAS1R3 Q7RTX0 1/20 0.36
TAS1R1 Q7RTX1 1/20 0.36
TAS1R2 Q8TE23 1/20 0.36
ALDH1A1 P00352 2/20 0.36
MAPT P10636 1/20 0.34
HSD11B1 P28845 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9924076 0.91 CHRM1 (0.41) CHRM1MCHR1DRD2CYP2C9MAPK14
SCHEMBL9924156 0.89 CHRM1 (0.45) CHRM1MCHR1DRD2CYP2C9MAPK14
SCHEMBL9924432 0.86 CHRM1 (0.43) CHRM1MCHR1CYP2C9MAPK14TAS1R3
SCHEMBL17206716 0.86 CHRM1 (0.43) CHRM1MCHR1CYP2C9MAPK14TAS1R3
SCHEMBL9924158 0.86 CHRM1 (0.42) CHRM1MCHR1DRD2CYP2C9MAPK14
SCHEMBL17206707 0.85 TAS1R3 (0.43) CHRM1MCHR1CYP2C9MAPK14TAS1R3
SCHEMBL17206712 0.85 CHRM1 (0.43) CHRM1MCHR1TAS1R3TAS1R1TAS1R2
SCHEMBL17206703 0.83 CHRM1 (0.41) CHRM1MCHR1DRD2CYP2C9MAPK14
SCHEMBL9923856 0.82 CHRM1 (0.42) CHRM1MCHR1CYP2C9MAPK14ALDH1A1
SCHEMBL9924276 0.81 EPHX2 (0.42) CHRM1MCHR1CYP2C9MAPK14EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9169199-B2 Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2015-10-27 US disclosed
WO-2012078867-A2 CYCLOALKYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF LYCERA CORPORATION (US) 2012-06-14 WO disclosed